EXONHIT
LIVE

Serial Number

79111670

Owner

EXONHIT S.A.

Filing Date

Nov 30, 2011

Add to watchlist:

No watchlists yet
View on USPTO

EXONHIT Trademark

Serial Number: 79111670 • Registration: 4281253

EXONHIT is a trademark filed by EXONHIT S.A. on November 30, 2011. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

EXONHIT S.A. (5 trademarks)

63-65 BOULEVARD MASSENA
PARIS 75013 , FR

Entity Type: 11

DIAXONHIT (3 trademarks)

63-65 boulevard Massena
F-75013 PARIS , FR

Entity Type: 99

Trademark Details

Filing Date

November 30, 2011

Registration Date

January 29, 2013

Published for Opposition

November 13, 2012

Cancellation Date

November 30, 2021

Goods & Services

Pharmaceutical products for the treatment of diseases, namely, Alzheimer disease and other neurodegenerative diseases and cancer; reagents and consumables for diagnostic purposes and diagnostic media intended for medical purposes, namely, reagents, consumables and media intended for tests, namely, tests based on blood biomarkers for identifying patients affected by diseases or those at risk of developing a disease and for identifying patients responding to specific personalized treatments; biological acidic products and preparations for pharmaceutical purposes, namely, pharmaceutical preparations for diagnosing diseases, namely, Alzheimer disease and other neurodegenerative diseases and cancer; capsules sold empty for medicines and diagnostic tests; chemico-pharmaceutical preparations for diagnosing, preventing and treating diseases, namely, Alzheimer disease and other neurodegenerative diseases and, cancer; biopharmaceutical products, namely, reagents, consumables, chemical entities and compounds for diagnosing, preventing and treating diseases, namely, Alzheimer disease and other neurodegenerative diseases and cancer ; chemical preparations for medical, pharmaceutical or veterinary purposes, namely, chemicals for diagnosing Alzheimer disease and other neurodegenerative diseases and cancer, especially chemical preparations for diagnosing diseases in the nature of neurodegenerative diseases and cancers; medical diagnostic products and clinical diagnostic products, namely, probes and kits for medical and clinical diagnosis comprised of nucleic acid libraries and nucleic acids on DNA chips; DNA libraries and RNA libraries for medical diagnostic purposes; nucleic acid sequences intended for use in chips for medical purposes and medical diagnostic purposes, namely, for decoding genes affected by diseases or revealing the transcriptomic signature of patients affected by diseases; enzymes or enzyme preparations for medical or veterinary purposes, namely, enzyme stabilizers and enzymatic substrates for use as ingredients in medicines for the treatment of diseases; reagents contained in diagnostic test kits for medical use for taking blood samples required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions

Chemical products and compositions, namely, nucleic acids attached to a solid medium for industrial and scientific use; fissile chemical elements intended for scientific research or laboratory research, namely, reagents, consumables, chemical entities and compounds; chemical preparations for nucleic acids attached to a solid medium for scientific purposes, chemical preparations for scientific analyses other than for medical or veterinary purposes; biological preparations other than for medical or veterinary purposes, namely, blood for the quantification of nucleic acid content; chemical preparations for scientific purposes other than for medical or veterinary use; chemical reagents or products for laboratory analyses, namely, nucleic acids for monitoring and analyzing the expression of genes, for identifying diagnostic targets and therapeutic products, and for conducting research on pharmacogenetics and genotoxicity in connection with pharmacology, food, chemistry, cosmetology, plant health and veterinary sciences; chemical preparations intended for scientific purposes, namely, libraries of nucleic acids for monitoring and analyzing the expression of genes, for identifying diagnostic targets and therapeutic products, and for leading research on pharmacogenetics and genotoxicity in connection with pharmacology, food, chemistry, cosmetology, plant health and veterinary sciences; chemical preparations intended for scientific purposes, namely, DNA fragments for decoding genes affected by diseases or for revealing the transcriptomic signature of patients affected by diseases, and DNA fragments for revealing and analyzing the expression of genes in connection with human medicine, pharmacological medicine and veterinary science

Medical services; veterinary services; medical assistance services; consultancy in the field of pharmacy, namely, to assist in the selection of individuals affected by diseases for the purpose of clinical trials and to offer targeted care solutions and personalized treatments; hospitals; pharmaceutical industry services, namely, to provide advice in the fields of biotechnology and pharmacy; and pharmacist's services to make up prescriptions, namely, geriatric and/or neurological services, in order to facilitate diagnoses and treatment; health care; telemedicine services

Surgical, medical, dental and veterinary apparatus and instruments, particularly for identifying, assessing the seriousness of, assessing prognoses of, and measuring the progression of diseases, namely, Alzheimer disease and other neurodegenerative diseases, and cancer; medical devices using DNA chips for analyzing blood; apparatus for analyzing blood; apparatus intended for medical diagnosis, namely, materials for taking blood contained in kits for taking blood samples and comprised of medical instruments for taking blood; medical instruments for taking blood, collecting of DNA for diagnosing diseases, and materials required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions, namely, tubes, syringes and storage containers; spoons for administering medicine; specially adapted containers for the application of medicines, namely, small bags and pouches for use in administering medicines; probes for medical purposes; syringes for medical purposes

Research and development for others of pharmaceutical molecules or biological markers for diagnostic purposes and medicines for treating diseases; chemical analyses; chemical research; chemical services, namely, analysis of RNA genes, tissues and blood samples; biotechnological scientific project studies for identifying people suffering from diseases and to measure the seriousness, prognoses, progression and conversion of the disease and to determine how patients respond to treatments, especially personalized treatments; research and development of new products for others; biological research; biotechnological research; technical research in the field of biotechnology; biotechnological analysis services; laboratory analyses, namely, quantification of nucleic acid content intended for medical and scientific research; consultancy in the field of biotechnology

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 26, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Jun 26, 2022 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jul 17, 2020 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jun 15, 2020 INTS
INVALIDATION PROCESSED
Jun 15, 2020 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 30, 2020 INTR
CANCELLED SECTION 71
Aug 30, 2019 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 29, 2018 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 20, 2014 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
May 25, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 29, 2013 FICS
FINAL DISPOSITION PROCESSED
Apr 29, 2013 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 29, 2013 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 29, 2013 R.PR
NOTIFICATION PROCESSED BY IB
Nov 18, 2012 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 13, 2012 NPUB
PUBLISHED FOR OPPOSITION
Nov 13, 2012 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 24, 2012 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 24, 2012 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 24, 2012 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 9, 2012 PREV
ASSIGNED TO LIE
Oct 5, 2012 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 22, 2012 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 21, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 21, 2012 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 21, 2012 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 27, 2012 GNFN
FINAL REFUSAL E-MAILED
Aug 27, 2012 GNFR
FINAL REFUSAL WRITTEN
Aug 27, 2012 CNFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 23, 2012 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 23, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 23, 2012 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 23, 2012 TROA
REFUSAL PROCESSED BY IB
Jun 11, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 18, 2012 RFCS
REFUSAL PROCESSED BY MPU
May 18, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 17, 2012 RFCR
NON-FINAL ACTION WRITTEN
May 16, 2012 CNRT
ASSIGNED TO EXAMINER
May 14, 2012 DOCK
APPLICATION FILING RECEIPT MAILED
May 8, 2012 MAFR
ASSIGNED TO EXAMINER
May 4, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 4, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 3, 2012 REPR